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1. Introduction 
Ischemic heart disease is one of the major threatens to human heath. Despite great advances in 
the treatment of it, the cardiac infarction caused by heart ischemia still represents a significant 
cause of morbidity and mortality. Recently, MSCs therapy has been emerged as one of the 
potential treatments for ischemic heart disease [1-4]. Although MSCs can differentiate into 
endothelial [5], cardiac cell [6], and secret a range of cytokines [7], there are mounting 
evidences which showed paracrine effect is the major mechanism for the therapeutic effect of 
MSCs in the ischemic heart [8-10]. Thus, the supplement of genes that can enhance 
angiogenesis or cell survival is one of the attractive strategies for MSCs therapy [11]. 
The Ang-1 has been reported to improve angiogenesis in ischemic heart [12,13]. Ang-1 has 
also been found as an apoptotic survival factor [14-16]. Therefore, the combination of Ang-1 
gene and MSCs would be an alternative method to enhance the effects of MSCs. However, 
when performing the combination of Ang-1 gene and MSCs therapy, a vector that has high 
transductive efficiency to MSCs is needed. 
Sendai virus is a murine parainfluenza virus type I, and is a single-stranded RNA virus. 
Sendai virus is considered to be non-pathogenic to humans [17]. Efficient gene transduction 
into various primary cultured cells and tissues by recombinant virus vector has been 
reported [18-22]. Furthermore, it replicates in the cytoplasma and poses no risk of 
integration into the genomic DNA. These characteristics of the Sendai virus make it a 
potential vector for combined gene and cell therapy. 
In our previously study, we found Sendai viral vector (SeV) has high transductive efficiency 
to MSCs even at low MOI [23]. To further investigate its clinical practicality, we infected SeV 
to the MSCs in vitro at low MOI with short time exposure. We also injected MSCs modified 
with SeVhAng-1 into the ischemic heart of rats to investigate its effect on angiogenesis and 
engraftment of MSCs in the ischemic heart. 
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2. Materials and methods 
2.1 Animals  
Lewis rats were obtained from the Animal Research Centre of the Fourth Military Medical 
University, Xi'an (China) and maintained on a 12-hour light: 12-hour dark in a 20–25°C 
environment. The Ethics Committee for Animal Experiments of the Fourth Military Medical 
University approved all animal work (Permit number: 20531) and the experimental 
protocols strictly complied with the institutional guidelines and the criteria outlined in the 
“Guide for Care and Use of Laboratory Animals”.  
2.2 Sendai virus vectors 
Sendai virus vectors containing the E.coli β-galactosidase gene (SeVLacZ) or the human 
angiopoietin-1 gene (SeVhAng-1) were used [24]. For the construction of genomic cDNA of 
SeVhAng1, the human Ang-1 open reading frame was cloned from a human cDNA library 
and amplified using the polymerase chain reaction with primers containing SeV-specific 
transcriptional regulation signal sequences:  
5’-TTGCGGCCGCCAAAGTTCAATGACAGTTTTCCTTTCCTTTCCTCTCTG-3’a 
nd5’ATTGCGGCCGCGATGAACTTTCACCCTAAGTTTTTCTTACTACGGTCAAAAATCT
AAAGTTCGAATCATCATAGTTGTGGAACG-3’, and was subsequently inserted into the 
NotI site of pSeV18+b(+) [25] to generate pSeVhAng-1. The pSeVhAng-1 was transfected 
into LLC-MK2 cells previously infected with vaccinia virus vTF7-3 [26], which expresses T7 
polymerase. The T7-drived full-length recombinant SeVhAng-1 RNA genomes were 
encapsulated with N, P and L proteins, which were derived from the respective 
cotransfected plasmids. Forty hours later, the transfected cells were injected into 10 day-old 
embryonated chicken eggs to amplify the recovered virus [27]. The Sendai virus titer was 
determined by a hemagglutination assay using chicken red blood cells, and the virus was 
stored at –70 ºC until use. 
2.3 MSCs source 
MSCs cultures were prepared according to the protocol reported previously. Briefly, under 
sterile conditions, the femur and tibia of 2 month-old male Lewis rats were excised, with 
special attention given to remove all connective tissue attached to bones. Bone marrow plugs 
were extracted from the bones by flushing the bone marrow cavity with Dulbecco’s 
modified Eagle’s medium (DMEM). Marrow plug suspension was dispersed by passing it 
through subsequent pipettes of decreasing sizes. After a homogenous cell suspension was 
achieved, the cells were plated, cultured in DMEM containing 10% fetal bovine serum, and 
incubated at 37°C humidified atmosphere with 5% CO2 for 3 days before the first medium 
change. 
2.4 In vitro SeV transduction 
After 70% conflulence of cultured MSCs in the dish, SeVLacZ at 10 MOI were infected to the 
MSCs with different time exposure (1 minute to 60 minutes). After 48 hr, both 
chmiluminescent assay of MSCs infected with SeVLacZ at 10 MOI with different time 
exposure and X-gal staining of MSCs infected with SeVLacZ at 10 MOI with 1 minute 
exposure were performed as previous described [28].  
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2.5 Expression of hAng-1 in MSCs by SeVhAng-1 transduction 
Human Ang-1 expression in MSCs was detected after 2 days of transduction with SeVhAng-
1 by Western blot. MSCs were washed twice with cold PBS and suspended in a cold lysis 
buffer (20 mmol/L HEPES, pH 7.5, 150 mmol/L NaCl, 1 mmol/L EDTA, 0.5% Triton X-100, 
protease inhibitors [complete, Roche]). Similar quantities of the soluble fractions (20µg) were 
separated by SDS-PAGE, transferred onto nitrocellulose membranes, and blocked overnight 
in blocking solution at 4oC. The membranes were incubated for 1 hr with mouse anti-human 
monoclonal antibodies to Ang-1 (Santa Cruz Biotechnology), followed by anti-mouse 
secondary antibody conjugated to horseradish peroxidase (Zymed, Inc., South San 
Francisco, CA) for 1 hr at room temperature. An enhanced chemiluminescence substrate 
system ECL Plus (Amersham Biosciences UK, Little Chalfont, UK) was used to visualize 
HRP. The ß-actin protein levels were assayed as the internal control. 
2.6 Animal model 
Lewis rats (female, weight 200-250 g) were used in the experiment. The rat was anesthetized 
with IP injection of ketamine(100mg/kg) and xylizine (10mg/kg), and intubated with a 17-
gague needle sheath. After intubation, the rat was supported with a rodent respirator. A left 
lateral thoractomy was made, the heart was exposed and LAD was ligated with 6-0 suture 
[12]. Immediately after LAD ligation, 5×106 MSCs were injected into the heart at 2 sites of 
peri-infarct area of the heart. 
2.7 Evaluation of heart function 
After 4 weeks of LAD ligation, the heart function was evaluated by echocardiography as 
previously described [29]. FS was used as a main index for the evaluation of heart function. 
2.8 Evaluation of infarct size 
We evaluated the infarct size of the heart as previously described [12]. Four weeks after 
myocardial infarction, rats were deeply anesthetized with inhalation of diethyl ether, 
injected with a mixture of ketamine hydrochloride (50 mg/kg) and xylazine (4 mg/kg), and 
killed by rapid exision of the heart. The excised hearts were immediately soaked in cold 
saline for 10s to remove excess blood from the ventricles and fixed in neutral-buffered 4% 
formalin for 48 h. Paraffin-embedded samples were sectioned at 10 μm, and Masson's 
trichrome staining was performed to delineate scar tissue from viable myocardium. 
Masson's trichrome-stained sections were captured as digital images and analyzed by NIH 
Image software. 
2.9 Capillary density measurement 
After 28 days of LAD ligation, the heart was harvest and snap-frozen in liquid nitrogen. 
Cryosections of 10 µm were made. The endothelial cells were stained with anti-CD31 
monoclonal antibody (Pharmingen) as first antibody, followed by a biotinylated anti-mouse 
IgG as second antibody, and an avidin-HRP conjugate for color reaction (DAB paraffin IHC 
staining module, Ventana Medical Systems, Inc., Tucson, AZ). The sections were observed 
under microscope, 5 fields were randomly selected in the peri-infarct area of each section, 
and CD31-positive cells were counted in a blinded manner. The number of CD 31-positive 
cells in each field was used as an index of capillary density. 
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2.10 Analysis of Ang-1 expression and its effect on p-Akt in the ischemic heart 
We injected MSCs modified with or without SeVhAng-1 into the ischemic heart of the rats 
and determined the effect of Ang-1 overexpression on p-Akt as previously described. In 
brief, after 2 days injection of MSCs modified with or without SeVhAng-1 into the 
ischemic heart, the heart was harvested and put into 4 ml lysis buffer, and incubated for 5 
min on ice. The cardiac muscle was homogenized with a mixing homogenizer (Kinematica 
AG, Littau switzerland). The homogenates were heated at 95 ºC for 10 min and 
centrifuged at 12,000g for 10 min. After determination of protein concentration in 
supernatants by BCA methods, total protein (40 µg) was subjected to SDS page in 5-20% 
Tris-glycine gels, subsequently transferred to nitrocellulose membranes and blocked 
overnight in blocking solution at 4oC. The membranes were incubated for 1 hr with mouse 
anti-human monoclonal antibodies to Ang-1 (Santa Cruz Biotechnology), p-Akt (ser473) 
and t-Akt (Signaling Technology, Beverly, MA) followed by anti-mouse secondary 
antibody conjugated to horseradish peroxidase (Zymed, Inc., South San Francisco, CA) or 
anti-rabbit secondary antibody conjugated to horseradish peroxidase (Amersham 
Biosciences UK, Buckinghamshire, England) for 1 hr at room temperature. An enhanced 
chemiluminescence substrate system ECL Plus (Amersham Biosciences UK, Little 
Chalfont, UK) was used to visualize HRP. 
2.11 TUNEL staining 
After 2 days injection of MSCs modified with or without SeVhAng-1, the heart was 
harvested, and cryosections were cut and randomly selected for TUNEL staining as 
described by manufacture (Roche).  
2.12 Real-time polymerase chain reaction for MSCs survival in the ischemic heart 
Real-time PCR was performed to detect Y-chromosomal DNA in the ischemic heart of 
female rat injected with male MSCs as previously reported [30]. In brief, after 2 days of 
MSCs injection, the heart was harvested, the DNA of the tissue was extracted with the 
Qiagen Kit (Qiagen, Mississauga, Ontario, Canada). Real-time PCR was performed with 
SYBR-Green (Applied Biosystems, Foster City, Calif). The SYBR-Green I dye binds to the 
double-stranded product, resulting in an increase in fluorescence detected by the ABI 
7900HT Sequence Detection System (Applied Biosystems). A specific sequence of rat Sry3 
gene in the Y chromosome was targeted. The genomic DNA taken from male MSCs was 
used to obtain a standard curve. The primer pairs were 5'-GCA TTT ATG GTG TGG TCC 
CGC GG-3' and 5'-GGC ACT TTA ACC CTT CGA TGA GGC-3'. The cycling conditions 
were 5 minutes at 50°C, 10 minutes at 95°C for activation of polymerase, and then 30 
seconds at 95°C for denaturation, 60 seconds at 62°C inducing annealing, and 30 seconds at 
72°C for extension. Forty-five cycles were used. After amplification, dissociation curves 
were obtained to discriminate between specific and nonspecific products. 
2.13 Statistical analysis 
Data were expressed as means ± standard deviations (SD). Statistical comparisons were 
performed using ANOVA followed by Bonferroni/Dunn testing. A p value less than 0.05 
was considered to be statistically significant. 
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3. Results 
3.1 Transductive efficiency of SeV to the MSCs 
To determine the transductive efficiency of SeV to MSCs, we infected SeVLacZ to MSCs at 
10 MOI with 1 minute exposure, and performed X-Gal staining after 48 h of infection. The 
results showed that Sendai viral vector almost had 100% transductive efficiency to MSCs 
even at 10 MOI with 1 mintue exposure. We also performed time course effect of the Sendai 
viral vector on the transductive efficiency to the MSC by chemiluminescent assay. 
Interestingly, we found that Sendai viral vector almost had the same protein expression at 
every time point checked (1 minute to 60 minutes). This indicates Sendai viral vector is ideal 
candidate for combined gene and cell therapy in clinical practice for its high transductive 
efficiency at low MOI with short time exposure. 
3.2 SeVhAng-1 transduction to MSCs mediated efficient Ang-1 expression 
To determine the expression of hAng-1 by SeVhAng-1-modified MSCs, Western blot were 
performed. We used a human Ang-1 antibody which has cross reaction with rat Ang-1 for 
Western blot. The result showed an obviously increased expression of Ang-1 in MSCs 
modified with SeVhAng-1. 
3.3 SeVhAng-1-modified MSCs injection decreased heart infarction and improved 
cardiac function after LAD ligation 
After 4 weeks of LAD ligation, the cardiac function was evaluated by echo. The FS was 39.0 
± 3.5, 32.0 ± 2.8 and 21.1 ± 3.3 in the SeVhAng-1-modified MSCs-, MSCs- and medium-
treated groups, respectively, and there was a significant difference between the SeVhAng-1-
modified MSCs and the medium (p<0.01), there was also a significant difference between 
SeVhAng-1-modified MSCs and sole MSCs (p<0.05). We then sacrificed rats after 4 weeks, 
the hearts were harvested, and Masson's trichrome staining was performed. The infarct size 
was 24.5 ± 4.8%, 32.5 ± 4.4% and 42.5 ± 5.1% in the SeVhAng-1-modified MSCs-, MSCs- and 
medium-treated groups, respectively, and there was a significant difference between the 
SeVhAng-1-modified MSCs and the medium (p<0.01), there was also a significant difference 
between SeVhAng-1-modified MSCs and sole MSCs (p<0.05). 
3.4 SeVhAng-1-modified MSCs injection increased capillary density in ischemic heart 
After 28 days of SeVhAng-1-modified MSCs injection, the immunostaining of CD31 on the 
cryosections of the cardiac muscle was carried out. The capillary density was  204.8 ± 18.3, 
150.2 ±1 6.2 and 77.4 ± 13.8 per field in the SeVhAng-1-modified MSCs-, MSCs- and 
medium-treated groups, respectively, and there was a significant difference between the 
SeVhAng-1-modified MSCs and the medium(p<0.01), there was also a significant difference 
between SeVhAng-1-modified MSCs and sole MSCs (p<0.05). 
3.5 Overexpression of Ang-1 increased p-Akt and decreased apoptosis in the 
ischemic heart 
MSCs secrete numerous cytokines and growth factors in hypoxic condition. However, the 
Ang-1 secretion is not obvious elevated [10,31]. Thus, we inferred that Ang-1, which is 
secreted by SeVhAng-1-modified MSCs, would play some role during early period of 
cardiac infarction. To prove this, we injected MSCs modified with or without SeVhAng-1 
www.intechopen.com
 Targets in Gene Therapy 
 
362 
into the ischemic heart of rats. First, we determined by Western blot whether the 
overexpression of Ang-1 by MSCs had an effect on the expression of p-Akt in the ischemic 
heart. The result showed that p-Akt expression obviously increased in ischemic heart 
treated by SeVhAng-1-modified MSCs, compared with that by sole MSCs. Because activated 
Akt has the effect of anti-apoptosis, we further determined whether increased p-Akt 
decreases apoptosis in the ischemic heart. We found that overexpression of Ang-1 by 
SeVhAng-1-modified MSCs decreased the apoptosis which may include endothelial cells, 
cardiac myocytes or MSCs in the ischemic heart, compared with that by sole MSCs. We 
further determined whether increased p-Akt improves survival of MSCs injected into the 
ischemic heart. By real time detection of sry gene in the female heart tissue samples at 2 days 
after sex-mismatched cell transplantation, We found that overexpression of Ang-1 by 
SeVhAng-1-modified MSCs significantly improved survival of MSCs per se in the ischemic 
heart (p<0.01), compared with that by sole MSCs. 
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Fig. 1. Transductive efficiency of Sendai viral vector to MSCs. A, MSCs were infected with 
10 MOI SeVLacZ with different time exposure, the chemiluminescent assay showed Sendai 
viral vector had high transductive efficiency to MSCs even with short time exposure, and 1 
minute exposure by SeVLacZ almost had the same transductive efficiency to the MSCs as 60 
minutes exposure did. B, X-gal staining of MSCs infected with 10 MOI Sendai viral vector. 
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Fig. 2. SeVhAng-1 mediated efficient hAng-1 expression in MSCs. Representative Western 
blot detection of hAng-1 expression after 10 MOI SeVhAng-1 infected to the MSCs with 1 
minute exposure. Lane 1, MSCs without transduction of SeVhAng-1; lane 2, MSCs with 
transduction of SeVhAng-1. The experiments were repeated 3 times. 
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Fig. 3. Effect of SeVhAng-1 modified MSCs on heart with LAD liagation. A, representive 
echo measurement of cardiac function at 28 days after LAD ligation. left, ischemic heart 
injected with medium; middle, ischemic heart injected with MSCs; right, ischemic heart 
injected with SeVhAng-1 modified MSCs. SeVhAng-1 modified MSCs significantly 
improved cardiac function, *p < 0.05 versus sole MSCs and **p < 0.01 versus medium, n＝5 
in each group. B, Masson's trichrome staining of the heart at 28 days after LAD ligation. left, 
ischemic heart injected with medium; middle, ischemic heart injected with MSCs; right, 
ischemic heart injected with SeVhAng-1 modified MSCs. SeVhAng-1 modified MSCs 
significantly decreased infarct size, *p < 0.05 versus sole MSCs and **p < 0.01 versus 
medium, n＝5 in each group.  
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Fig. 4. A, capillary density at 28 days after injection of SeVhAng-1 modified MSCs into the 
ischemic heart. Left, heart injected with medium; middle, heart injected with sole MSCs; 
right, heart injected with SeVhAng-1-modified MSCs, magnification, ×400. B, SeVhAng-1 
significantly increased the capillary density compared with controls. *p < 0.01 versus 
medium and *p < 0.05 versus MSCs, n＝5 in each group. 
4. Discussion 
In the present study, we found that Sendai viral vector had high transductive efficiency to 
MSCs even at low MOI with short time exposure. Both MSCs modified with SeVhAng-1 and 
MSCs improved the cardiac function in rats after heart infarction. However, MSCs modified 
with SeVhAng-1 had better improvement of cardiac function, compared with sole MSCs. 
This indicated that SeVhAng-1-modified MSCs could serve as a more effective therapy for 
ischemic heart disease. 
Among various vectors, adenoviral vector is widely used for combination of gene and cell 
therapy in recent years. However, because of lower expression of the CAR receptor for the 
binding of adenovirus in MSCs, the transductive efficiency of adenoviral vector to the MSCs 
is not so satisfactory, especially at low MOI [23, 31]. SeV has been proved to have high 
transductive efficiency in a broad range of tissues, including the airway epithelial cells, 
vasculature tissues, skeletal muscles, activated T cells, stem cells and neural tissues. In our 
previously study, we found Sendai viral vector (SeV) has high transductive efficiency to 
MSCs even at low MOI [23]. In present study, we further found that SeV had high 
transductive efficiency to MSCs at low MOI with short time exposure. This characteristic of 
SeV overcomes the shortcoming of needing relatively long time exposure to the MSCs by 
current available vectors such as adenoviral vector, and makes it an ideal vector for 
combined stem cell and gene therapy in clinical practice. 
Although MSCs can differentiate into cardiomyocytes and endothelial cells, the magnitude 
of incorporation of MSCs into vascular structures or regenerating cardiomycytes is too low 
to explain the functional recovery of ischemic heart by MSCs. Kinnaird et al found that 
MSCs can secret a range of cytokines such as VEGF and bFGF in hypoxic condition and 
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suggested the paracrine mechanism of MSCs is one of the major causes of angiogenetic effect 
by MSCs [9,10]. Nevertheless, hypoxic condition does not increase Ang-1 expression in MSCs 
[10, 32]. Because Ang-1 plays an important role in angiogenesis, the supplement of Ang-1 
seems to have significant importance for MSCs in treating ischemic heart disease. In the 
present study, we got a high expression of Ang-1 by transduction of SeVhAng-1 to the MSCs, 
which had an enhanced angiogenesis effect in the ischemic heart compared with sole MSCs. 
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Fig. 5. Effect of overexpression of Ang-1 on p-Akt and MSCs survival in the ischemic heart. 
A, lane 1, heart injected with MSCs; lane 2, heart injected with SeVhAng-1- modified MSCs. 
SeVhAng-1- modified MSCs obviously increased expression of Ang-1 and p-Akt in the 
ischemic heart. The experiments were repeated 3 times. B, a, heart injected with MSCs; b, 
heart injected with MSCs modified with SeVhAng-1. Apoptotic cell were stained brown, 
magnification, ×400. SeVhAng-1-modified MSCs obviously decreased apoptosis, compared 
with the sole MSCs. C , Real-time polymerase chain reaction for sry gene in the female heart 
muscle samples at 2 days after sex-mismatched cell transplantation. The fold change in sry 
gene expression in different animal groups was calculated. The results showed SeVhAng-1-
modified MSCs significantly improved MSCs survival, compared with the sole MSCs. *p< 
0.01 versus sloe MSCs. 
The high rate of death occurs after MSCs transplantation because of inflammation, loss of 
survival signal from matrix attachments [33] and cytotoxic factors in the ischemic heart [34]. 
For these reasons, the enhancement of MSCs engraftment in hostile circumstance is 
becoming one of attractive strategies to improve its therapeutic effects [35-38]. Ang-1 
prevents endothelial cell apoptosis [16] and promotes cardiac muscle survival [39] via 
activation of Akt pathways. Accordingly, overexpression of Ang-1 by SeVhAng-1-modified 
MSCs may also have protective effect to MSCs per se which is beneficial to the engraftment 
of MSCs in the ischemic heart. Indeed, we found SeVhAng-1-modified MSCs significantly 
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increased p-AKT expression, which improved survival of MSCs injected into the ischemic 
heart. This protective effect by SeVhAng-1-modified MSCs would be beneficial to the 
enhancement of angiogenesis during the period of heart ischemia. 
Our study indicated that Sendai viral vector has high transductive efficiency to the MSCs 
even at low MOI with short time exposure, and MSCs modified with SeVhAng-1 enhances 
the angiogenetic effect of MSCs. In addition, the SeVhAng-1 modification increases survival 
of MSCs in the ischemic heart. SeVhAng-1-modified MSCs may serve as a more effective 
and practical tool in dealing with ischemic heart disease. 
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